Testosterone Cypionate Injection — Class II drug recall D-0363-2025
Ongoing recall by Eugia US LLC, reported 2025-04-23, distributed nationwide. cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.
| Recall number | D-0363-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Eugia US LLC, East Windsor, NJ, United States |
| Recall initiated | 2025-04-10 |
| Classified | 2025-04-14 |
| Reported by FDA | 2025-04-23 |
| Distributed | Nationwide (US) |
| Quantity | 36,816 vials |
| Reason classes | cgmp |
| NDC | 55150-0276, 55150-0276-01, 55150-0277, 55150-0277-01, 55150-0278, 55150-0278-01 |
| Lot numbers | 1TC24075A |
| Expiration dates | 2026-11-30 |
Product
Testosterone Cypionate Injection, USP, CIII, 200mg per mL, Rx only, 1mL Single-Dose Vial, Distributed by Eugia US LLC, E. Windsor, NJ, Manufactured by: Eugia Specialties Limited, Telangana State, India, NDC 55150-277-01
Reason for recall
cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0363-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.